Key Inclusion Criteria:

- ≥ 18 years old.
- Body mass index (BMI) of ≥ 18 kg/m^2.
- Evidence of bronchiectasis per CT.
- Evidence of chronic pulmonary Pseudomonas aeruginosa infection.
- Willing to undergo sputum induction procedures at designated study visits, and willing
to provide expectorated sputum samples at all other timepoints (for subjects who are
able to expectorate).
- FEV1 ≥ 35% of predicted normal [per Global Lung Function Initiative (GLI) standards]
at Screening.
- For Cohort A: have not received chronic inhaled antipseudomonal antibiotics regimen
for at least 3 months prior to Visit 1.
- For Cohort B: have received chronic inhaled antipseudomonal antibiotics regimen for at
least 3 months prior to Visit 1.

Key Exclusion Criteria:

- Abnormal vital signs at Screening.
- History of lung transplantation.
- History of cystic fibrosis.
- History of α1-antitrypsin deficiency.
- History of primary or acquired immunodeficiency syndromes.
- History of COPD.
- History of pulmonary malignancy or any other malignancy requiring treatment.
- History of prolonged QT syndrome.
- History of hemoptysis.
- Recent significant weight loss.
- Recent use of supplemental oxygen during the day while at rest.
- Recent use of cigarettes, cigars, or pipes, or used tobacco or other nicotine source
by vaping.
- Recent changes in either the treatment regimen or initiation of treatment with: oral
macrolides, hypertonic saline, mucolytics, bronchodilator medications, or oral
corticosteroids.
- Currently receiving treatment for active infection at any site.
- Female pregnant of breastfeeding.

Eligibility last updated 12/30/22. Questions regarding updates should be directed to the study team contact.